Show simple item record

dc.contributor.authorGoletti, Delia
dc.contributor.authorLindestam Arlehamn, Cecilia S
dc.contributor.authorScriba, Thomas J
dc.contributor.authorAnthony, Richard
dc.contributor.authorCirillo, Daniela Maria
dc.contributor.authorAlonzi, Tonino
dc.contributor.authorDenkinger, Claudia M
dc.contributor.authorCobelens, Frank
dc.date.accessioned2018-11-20T12:00:37Z
dc.date.available2018-11-20T12:00:37Z
dc.date.issued2018-11
dc.identifier.citationCan we predict tuberculosis cure? What tools are available? 2018, 52 (5) Eur. Respir. J.en
dc.identifier.issn1399-3003
dc.identifier.pmid30361242
dc.identifier.doi10.1183/13993003.01089-2018
dc.identifier.urihttp://hdl.handle.net/10029/622300
dc.description.abstractAntibiotic treatment of tuberculosis takes ≥6 months, putting a major burden on patients and health systems in large parts of the world. Treatment beyond 2 months is needed to prevent tuberculosis relapse by clearing remaining, drug-tolerant Mycobacterium tuberculosis bacilli. However, the majority of patients treated for only 2-3 months will cure without relapse and do not need prolonged treatment. Assays that can identify these patients at an early stage of treatment may significantly help reduce the treatment burden, while a test to identify those patients who will fail treatment may help target host-directed therapies.In this review we summarise the state of the art with regard to discovery of biomarkers that predict relapse-free cure for pulmonary tuberculosis. Positron emission tomography/computed tomography scanning to measure pulmonary inflammation enhances our understanding of "cure". Several microbiological and immunological markers seem promising; however, they still need a formal validation. In parallel, new research strategies are needed to generate reliable tests.
dc.language.isoenen
dc.rightsinfo:eu-repo/semantics/closedAccessen
dc.titleCan we predict tuberculosis cure? What tools are available?en
dc.typeArticleen
dc.identifier.journalEur Respir J 2018; 52(5): pii: 1801089en
html.description.abstractAntibiotic treatment of tuberculosis takes ≥6 months, putting a major burden on patients and health systems in large parts of the world. Treatment beyond 2 months is needed to prevent tuberculosis relapse by clearing remaining, drug-tolerant Mycobacterium tuberculosis bacilli. However, the majority of patients treated for only 2-3 months will cure without relapse and do not need prolonged treatment. Assays that can identify these patients at an early stage of treatment may significantly help reduce the treatment burden, while a test to identify those patients who will fail treatment may help target host-directed therapies.In this review we summarise the state of the art with regard to discovery of biomarkers that predict relapse-free cure for pulmonary tuberculosis. Positron emission tomography/computed tomography scanning to measure pulmonary inflammation enhances our understanding of "cure". Several microbiological and immunological markers seem promising; however, they still need a formal validation. In parallel, new research strategies are needed to generate reliable tests.


This item appears in the following Collection(s)

Show simple item record